| Interagency advisory group - immune assay variant updates for Project NextGen |
Committee, Work group, Advisory group, or Task Force |
ASPR, BARDA, CDC, FDA |
NIAID |
Advisory group to provide expert recommendation regarding the need to develop new assays for variants supporting development of candidate vaccines in the project next gen portfolio and assessment of their correlates of protection |
| Interagency Agreement between NIH OLAW and ASPR Biomedical Advanced Research and Development Authority (BARDA) |
Other |
BARDA |
OD/OER |
OLAW technical and administrative services provided to ensure compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) for BARDA awards involving research with live vertebrate animals. |
| Interagency Agreement between NIH OLAW and Centers for Disease Control and Prevention (CDC) |
Other |
CDC |
OD/OER |
OLAW technical and administrative services provided to ensure compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) for CDC awards involving research with live vertebrate animals. |
| Interagency Agreement between NIH OLAW and Food & Drug Administration (FDA) |
Other |
FDA |
OD/OER |
OLAW technical and administrative services provided to ensure compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) for FDA awards involving research with live vertebrate animals. |
| Interagency Agreement NTP/NIEHS and NCTR/FDA |
Other |
FDA |
NIEHS |
Collaborative working relationship between NTP/NIEHS and NCTR/FDA |
| Interagency Artificial Pancreas Working Group |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIBIB, NIDDK |
The Interagency Artificial Pancreas Working Group is a group of multi-disciplined scientists and clinicians from the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) to support the Artificial Pancreas Initiative. The goals of this initiative are to provide infrastructure for narrowing the gap between basic biomedical knowledge and clinical application of novel technologies, and to cross-fertilize and partner with stakeholders in order to identify and overcome the clinical and scientific challenges to the development of an artificial pancreas. Through collaborative efforts, such as workshops, the group strives to develop innovative strategies to achieve their goals. |
| Interagency Autism Coordinating Committee (IACC) |
Committee, Work group, Advisory group, or Task Force |
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA |
NICHD, NIDCD, NIEHS, NIMH, NINDS, OD/DPCPSI/OBSSR |
The Interagency Autism Coordinating Committee (IACC) is a federal advisory committee charged with coordinating federal activities concerning autism spectrum disorder (ASD) and providing advice to the Secretary of Health and Human Services on issues related to autism. Membership of the Committee includes a wide array of federal departments and agencies involved in ASD research and services, as well as public stakeholders, including self-advocates, family members of children and adults with ASD, advocates, service providers, and researchers, who represent a variety of perspectives from within the autism community. The Committee members provide a wide range of expertise and experiences and allow the IACC to address the breadth of issues and challenges faced by individuals and families affected by autism. The IACC was reauthorized under the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2019. In fiscal year 2024, the IACC held four full committee meetings on: October 11, 2023; January 24, 2024; April 17, 2024; and July 10, 2024. The IACC also held an IACC Strategic Plan Update Meeting on September 23, 2024. The IACC is currently authorized under the Autism CARES Act of 2024. |
| Interagency Cancer Diagnostic Devices (CD2) Task Force for Near-Patient Use |
Committee, Work group, Advisory group, or Task Force |
FDA, HRSA |
NCI |
The NCI, FDA, Health Resources and Services Administration (HRSA) and CMS partnered in late 2019 to establish the Interagency Cancer Diagnostic Devices (CD2) Task Force for Near-Patient Use. Near-patient diagnostics generally refers to a system whereby a sample is analyzed, and the results are delivered in the same location and while the patient is being evaluated. Near-patient diagnostics are often offered at point-of-care settings where at-home tests may be available with a prescription or purchased over-the-counter. CD2 is a collaborative effort among four federal partners working together within and across their respective missions to bring more soluctions to: detect and diagnose cancer earlier; enhance identification of patients at high risk of developing cancer and surveillance of those at risk of cancer recurrence; improve monitoring of patient response during cancer treatment; and reduce the effect of health disparities and equitably extend the benefits of health care to all populations. The primary goal of this initiative is to develop opportunities that accelerate the pace by which point of care diagnostic devices get to patients for the earlier detection and screening of cancer. The Task Force and Initiative will address cancer types for geographically isolated, medically underserved, and otherwise vulnerable communities, with emphasis to: 1) Cancer types with clear, existing need and highly prevalent, for example cervical cancer; and 2) Cancer types that have evidence of future need from emerging at-risk populations, for example liver cancers derived from nonalcoholic steatohepatitis (NASH). On Friday, September 17, 2021, leadership from the National Cancer Institute (NCI), Food and Drug Administration (FDA), and Health Resources and Services Administration (HRSA) signed a Memorandum of Understanding (MOU) to support solutions for early cancer detection and diagnosis to improve patient outcomes, quality of life, and reduce health disparities among medically underserved, geographically isolated, and otherwise vulnerable populations through the interagency CD2 task force. |
| Interagency Collaborative Animal Research Education (ICARE) Training Project |
Training Initiative |
ASPR, BARDA, FDA |
OD/OER |
The Interagency Collaborative Animal Research Education (ICARE) Academies and Train the Trainer Institutes use active learning to train participants to meet their responsibilities for animal welfare oversight. The program empowers accountability for facts and conceptual understanding of Federal standards through the study of realistic problems encountered in animal care and use programs. Faculty includes subject matter experts from biomedical research institutions and federal agencies, including National Institutes of Health (NIH) and United States Department of Agriculture (USDA). Institutional Animal Care and Use Committee members, staff, institutional officials, veterinarians, animal facility personnel, administrators, consultants, as well as compliance and regulatory personnel involved in the humane use of animals in research all may participate in the ICARE program |
| Interagency Collaborative to Advance Research in Epilepsy (ICARE) |
Committee, Work group, Advisory group, or Task Force |
AHRQ, CDC, FDA, HRSA |
FIC, NCATS, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIMH, NINDS |
The Interagency Collaborative to Advance Research in Epilepsy (ICARE) is an interagency epilepsy working group that includes broad representation across the National Institutes of Health (NIH) institutes and centers (ICs) involved in epilepsy-related research, as well as across the Department of Health and Human Services other Federal agencies multiple epilepsy research organizations, and patient advocacy groups with a primary focus on biomedical research. The purpose of this group, which is led by the National Institute of Neurological Disorders and Stroke, is to increase communication among institutes and agencies sponsoring epilepsy-related research and to explore opportunities for increased coordination. The group’s annual meetings provide a forum for sharing information about ongoing and planned epilepsy research activities, highlighting advances, discussing needs and opportunities, and promoting increased collaboration toward common research goals. https://www.ninds.nih.gov/Current-Research/Focus-Research/Focus-Epileps… |